Zhejiang East Asia Pharmaceutical Co., Ltd. Class A

Zhejiang East Asia Pharmaceutical Co., Ltd. Class A

SSSE:605177
17.22
CNY
-0.61
(-3.42%)
-1.16EPS
1.96BMarket Cap
Apr 29Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
9.13
9.28
10.03
11.62
10.09
6.24
10.39
11.97
10.71
8.22
9.15
Basic EPS, GAAP
0.89
0.71
1.28
1.98
1.31
0.6
0.92
1.07
-0.9
-0.72
-1.34
Free Cash Flow per Basic Share
0.19
0.81
1.34
1.87
0.98
-1.28
-1.39
-2.75
-3.29
-3
- -
Dividend per Share
0.23
0.22
0.09
0.76
0.21
0.34
0.21
0.32
0.37
0.08
0.06
Book Value per Share
5.62
7.42
8.34
9.95
15.23
15.48
16.2
17.74
16.34
15.74
14.85
Tangible Book Value per Share
4.93
6.81
7.75
9.36
14.82
15.08
15.64
17.19
15.62
14.88
13.92
Basic Weighted Avg Shares
75
79
85
85
87
114
114
113
112
114
113
Sales/Revenue/Turnover
684
729
857
988
882
712
1,180
1,356
1,198
940
1,035
Operating Margin (%)
15.27
12.57
17.18
20.45
15.29
8.1
8.51
10.01
3.06
-3.25
-2.69
Depreciation Expense
52
56
57
60
63
70
94
112
137
155
- -
Net Income, GAAP
67
56
109
168
114
68
104
121
-101
-82
-152
Effective Tax Rate (%)
17.68
19.41
14.93
13.39
12.06
11.12
9.27
9.98
- -
- -
- -
Profit Margin (%)
9.75
7.65
12.76
17.04
12.98
9.62
8.85
8.94
-8.4
-8.76
-14.66
Working Capital
-98
89
177
304
1,071
723
619
1,049
615
503
481
LT Debt
10
3
- -
10
- -
2
24
583
682
759
789
Total Equity
426
632
711
848
1,730
1,758
1,840
2,015
1,875
1,806
1,703
Return on Invested Capital (%)
- -
6.55
13.09
20.35
9.03
4.01
5.86
5.24
- -
- -
- -
Return on Capital (%)
- -
8.3
13.43
20.41
8.82
3.92
5.65
5.31
- -
- -
- -
Return on Common Equity (%)
- -
10.53
16.28
21.6
8.88
3.93
5.8
6.29
-5.18
-4.48
-8.49

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
235
197
133
LT Borrowings
752
778
783
LT Finance Leases
7
7
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
115
115
115
Market Capitalization
2,042
2,392
1,963

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,193
1,114
976
Cash, Cash Equivalents & STI
364
369
315
Accounts Receivable, Net
147
138
94
Inventories
537
450
415
Total Current Liabilities
691
597
496
Payables & Accruals
- -
- -
- -
ST Debt
235
197
133
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1.04%
-3.67%
Free Cash Flow
- -
-30.53%
-6.8%
Net Income, GAAP
- -
-34.55%
-18.15%
Sales/Revenue/Turnover
- -
5.64%
-21.54%
Total Cash Common Dividend
- -
12.42%
-79.29%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
353
296
315
235
1,198
2025
191
225
- -
344
940
2026
265
202
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
0.07
0.11
-1.3
-0.9
2025
-0.06
-0.21
- -
-0.09
-0.72
2026
-0.31
-0.73
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.35
0.01
0.37
2025
0.01
0.01
- -
0.02
0.08
2026
0.02
0.01
- -
- -
- -

Company Description

CEO
Cheng Chi
Full Time Employees
1,514
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Chamber of Commerce Building Taizhou ZH China 318020
IPO Date
Nov 25, 2020
Website
eapharm.cn
Business
Zhejiang East Asia Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical chemicals, active pharmaceutical ingredients (APIs), intermediates, tablets, granules, and capsules. Its core products include quinolones synthetic antibacterial agents such as ofloxacin and levofloxacin; antifungal drugs including ketoconazole and tioconazole; gastrointestinal medications; semi-synthetic cephalosporin antibiotics and intermediates like cefaclor, cefdinir, cefixime, cefmetazole sodium, and cefotetan disodium; carbapenem antibiotics such as faropenem; antiviral agents; central nervous system medications including donepezil hydrochloride; respiratory drugs; antiallergic agents; antineoplastic agents and tumor adjuvant drugs. The company also provides treatments for cardiovascular, anti-aging dementia, digestive system, diabetic neuropathy, and anti-pathogenic microorganisms. It operates primarily in China but serves customers across Europe, the United States, Southeast Asia, and internationally through an extensive sales network. Founded in 1992 and headquartered in Taizhou City, Zhejiang Province, China, Zhejiang East Asia Pharmaceutical employs over 1,000 personnel and holds various certifications including CGMP, European Union EDQM, and Japan PMDA. Recent years have seen the company enhance its production capabilities and customize product offerings through its own R&D team and production lines, maintaining a strategic focus on quality and cost efficiency. It has also strengthened its position as a national high-tech enterprise and secured long-term cooperative relationships globally, reflecting its business expansion and operational enhancements within the last two years.